Europe based researchers Brodie et al. provided class 1 evidence of efficacy of levetiracetam (Keppra®, UCB Inc) as a monotherapy to control epilepsy in patients who don't respond to or can't tolerate existing treatments, according to a study published in the February 6, 2007 issue of Neurology®.
Study involved nearly 600 adults who had at least two seizures in the previous year to the drug levetiracetam or to controlled-release carbamazepine. Compare to carbamazepine, levetiracetam found to be well-tolerated, safe and easy-to-use drug (minimal drug interactions, less protein bounding and no cytochrome P450 isoenzymes dependent metabolism). Levetiracetam is currently approved as an adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy; and in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.
[Ref.:NEUROLOGY 2007;68:402-408 Keppra® official website]
This page may not show current updates. View original posts at Blog Junction | SBAmin.com or Click here
for low graphic version
| Receive automatic email updates via
Feedburner /
Feedblitz |
Contact S B Amin
| Receive automatic email updates via
Feedburner /
Feedblitz |
Contact S B Amin
Monday, February 05, 2007
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment